Last reviewed · How we verify

NCT04479579

Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery

Completed Phase 4 Last updated 22 April 2022
What this trial tests

Phase 4 trial testing Apixaban 2.5 milligram in Neoplasms Malignant in 53 participants. Completed in 6 November 2021.

Timeline
22 February 2021
Primary endpoint
31 October 2021
6 November 2021

Quick facts

Lead sponsorMcMaster University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment53
Start date22 February 2021
Primary completion31 October 2021
Estimated completion6 November 2021
Sites2 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

McMaster University

Who can join

18 and older, any sex, with Neoplasms Malignant or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, twin-center, cohort study in patients discharged from the hospital after major abdominal or pelvic cancer surgery for cancer. This study is designed to evaluate the adherence to extended deep vein thrombosis prophylaxis (DVT) with the direct oral anticoagulant apixaban on the background of historical data from the investigator's center on low-molecular-weight heparin (LMWH) substandard adherence in the same setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Apixaban 2.5 milligram

Trials testing the same drug.

Other recruiting trials for Neoplasms Malignant

Currently open trials in the same condition.

Other McMaster University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04479579.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing